Skip to main content
    O

    Ocugen Inc (OCGN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.77
    -0.05 (-6.62%)

    Market Cap: $280.88M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Ocugen Inc (OCGN) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Ocugen are Opus Genetics (IRD), Oculis Holding AG Ordinary shares (OCS) and Ovid Therapeutics (OVID). By market cap, Ocugen ranks 9th of the 13 companies on this page; Neurogene (NGNE) is the largest at $495.37M.

    Peer Comparison

    OCGN's ROIC of 271.0% is above the peer median of -42.2%, and its revenue growth of 11.4% is above the median of 0.0%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Ocugen (OCGN)$280.88MN/A54.9x0.0%271.0%11.4%0.00%
    Opus Genetics, Inc. (IRD)$384.68MN/A52.0x0.0%-145.1%-63.1%0.00%
    Oculis Holding AG Ordinary shares (OCS)$425.67MN/AN/A0.0%N/A-97.1%0.00%
    Ovid Therapeutics Inc (OVID)$479.38MN/A335.8x0.0%N/A-88.3%0.00%
    Rocket Pharmaceuticals Inc (RCKT)$256.82MN/AN/A0.0%-2.3%0.0%0.00%
    PepGen Ltd (PEPG)$410.98MN/AN/A0.0%N/A0.0%0.00%
    Atrium Therapeutics, Inc. Common Stock (RNA)$162.00MN/A3.3x-180.9%-44.5%24.2%0.00%
    Pyxis Oncology Inc (PYXS)$188.98MN/A11.6x0.0%N/A0.0%0.00%
    enGene Therapeutics Inc. (ENGN)$161.51MN/AN/A0.0%-42.2%0.0%0.00%
    Fulcrum Therapeutics Inc (FULC)$287.96MN/AN/A0.0%N/A-100.0%0.00%
    Editas Medicine Inc (EDIT)$334.92MN/A5.6x-145.0%-42.3%37.4%0.00%
    Neurogene Inc (NGNE)$495.37MN/AN/A0.0%-28.5%0.0%0.00%
    Tevogen Bio Holdings Inc. (TVGN)$406.59MN/AN/A0.0%2022.8%0.0%0.00%
    Peer median$359.80MN/A11.6x0.0%-42.2%0.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Ocugen, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Opus Genetics, Inc. (IRD)
    Opus Genetics, Inc. (IRD) is a pioneering biotechnology company dedicated to advancing gene therapies for rare retinal diseases that affect vision.
    IRD competitors
    Oculis Holding AG Ordinary shares (OCS)
    Oculis Holding AG, a biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye.
    OCS competitors
    Ovid Therapeutics Inc (OVID)
    Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medications for patients and families with neurological disorders in the United States.
    OVID competitors
    Rocket Pharmaceuticals Inc (RCKT)
    Rocket Pharmaceuticals, Inc., is a cross-platform biotechnology company focused on developing gene therapies for rare and devastating pediatric diseases.
    RCKT competitors
    PepGen Ltd (PEPG)
    PepGen Inc., a clinical-stage biotechnology company, is focused on the development of oligonucleotide therapeutics for use in the treatment of serious...
    PEPG competitors
    Atrium Therapeutics, Inc. Common Stock (RNA)
    Avidity Biosciences, Inc., a biopharmaceutical company, is dedicated to the development of oligonucleotide-based therapies.
    RNA competitors
    Pyxis Oncology Inc (PYXS)
    Pyxis Oncology, Inc., a preclinical biotechnology company, is dedicated to developing antibody-drug conjugate (ADC) and monoclonal antibody (mAb)...
    PYXS competitors
    enGene Therapeutics Inc. (ENGN)
    enGene Holdings Inc., through its subsidiary enGene, Inc., is a clinical-stage biotechnology company that develops genetic medicines through the delivery...
    ENGN competitors
    Fulcrum Therapeutics Inc (FULC)
    Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products to improve the lives of patients with genetically defined...
    FULC competitors
    Editas Medicine Inc (EDIT)
    Editas Medicine, Inc., a clinical-stage genome editing company, is focused on developing transformative genomic drugs to treat a variety of serious diseases.
    EDIT competitors
    Neurogene Inc (NGNE)
    Neurogene Inc. is an innovative biotechnology company at the forefront of developing advanced gene therapies for rare neurological disorders...
    NGNE competitors
    Tevogen Bio Holdings Inc. (TVGN)
    Tevogen Bio Holdings Inc. is a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology...
    TVGN competitors

    Frequently Asked Questions About OCGN

    Who are Ocugen's main competitors?

    The companies most similar to Ocugen include Opus Genetics (IRD), Oculis Holding AG Ordinary shares (OCS), Ovid Therapeutics (OVID), Rocket Pharmaceuticals (RCKT) and PepGen (PEPG), listed from the closest match.

    Who is Ocugen's biggest competitor?

    Neurogene (NGNE) is the largest of the similar companies at $495.37M; Opus Genetics (IRD) is the closest match by business profile, size, sector and industry.

    How does OCGN stock compare with its competitors?

    OCGN's P/S is 54.9x against a peer median of 11.6x; its net margin is 0.0% against a peer median of 0.0%.

    Which of Ocugen's competitors pays a higher dividend?

    Ocugen pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Ocugen bigger than its competitors?

    No. Ocugen is 9th by market cap among the 13 companies on this page; the largest is Neurogene (NGNE) at $495.37M.